Multiplex Assays Market by Product Type (Consumables, Instruments, Services), Assay Type (Cell-Based Multiplex Assays, Nucleic Acid-Based Multiplex Assays, Protein-Based Multiplex Assays), Application, End User - Global Forecast 2025-2032
Description
The Multiplex Assays Market was valued at USD 2.81 billion in 2024 and is projected to grow to USD 3.10 billion in 2025, with a CAGR of 10.94%, reaching USD 6.45 billion by 2032.
Unlocking the Transformative Power and Strategic Significance of Multiplex Assays in Advancing Analytical Capabilities Across Diverse Industries
Multiplex assays have emerged as a pivotal analytical approach that empowers scientists and decision-makers with simultaneous detection and quantification of multiple analytes in a single assay. By integrating advanced detection technologies with robust data analysis platforms, these assays streamline workflows, enhance data richness, and significantly reduce sample volume requirements. In recent years, academic and industrial laboratories alike have recognized the strategic value of multiplex assays in accelerating research and development timelines, facilitating diagnostic innovation, and optimizing quality control processes across a diverse range of applications.
Furthermore, rapid technological advancements have enabled a shift from traditional single-analyte assays to multiplex formats that accommodate complex biological matrices with higher throughput and greater sensitivity. Consequently, researchers can now address multifactorial questions in areas such as biomarker validation, genomics, and proteomics with unprecedented efficiency. Ultimately, the adoption of multiplex assays represents a transformative milestone in analytical science, setting the stage for more precise, cost-effective, and scalable solutions that will shape the future of diagnostics, environmental monitoring, food safety testing, and beyond.
How Convergence of Technological Innovations and Interdisciplinary Approaches Is Redefining Multiplex Assay Capabilities
Recent years have witnessed an accelerating convergence of technological innovation and cross-disciplinary collaboration that is redefining the multiplex assay landscape. As microfluidic platforms, advanced optical detection systems, and mass spectrometry techniques mature, they are increasingly integrated into hybrid workflows that deliver richer datasets and enhanced dynamic range. Moreover, the proliferation of machine learning algorithms and cloud-based analytics has facilitated real-time interpretation of complex multiplex results, driving a paradigm shift from reactive to predictive decision-making.
In parallel, regulatory bodies have begun to issue updated guidance that acknowledges the unique advantages and validation requirements of multiplex formats, thereby reducing barriers to clinical adoption and commercial distribution. Additionally, academic consortia and industry partnerships are fostering standardized protocols and reagent libraries, enhancing reproducibility and interoperability across laboratories. This collective momentum is transforming multiplex assays from niche research tools into mainstream platforms that underpin next-generation diagnostics, personalized medicine initiatives, and advanced environmental and food safety monitoring.
Examining the Far-Reaching Consequences of New Tariff Measures on Multiplex Assay Supply Chains and Cost Structures
The implementation of revised United States tariff measures in 2025 has introduced notable complexities to the global multiplex assay supply chain. As import duties on key assay components-including beads, probes, specialty reagents, and detection instruments-have increased, manufacturers and end users are compelled to reassess sourcing strategies and cost structures. Consequently, many stakeholders are exploring nearshoring options to mitigate exposure to tariff volatility, while others are negotiating long-term supplier agreements to lock in more favorable terms.
However, the impact extends beyond procurement expenses. Tariff-induced lead time extensions and logistical challenges have prompted laboratories to adopt lean inventory management practices and diversify vendor portfolios. Furthermore, heightened cost pressures have accelerated interest in digital assay formats and modular instrument platforms that minimize dependency on proprietary consumables. Despite these headwinds, the industry has responded with adaptive strategies that preserve both operational continuity and innovation momentum, ensuring that multiplex assay development remains resilient and future-ready.
Uncovering Critical Market Dynamics Through Detailed Segmentation Across Product, Assay, Application, and End User Domains
A comprehensive segmentation analysis reveals distinct growth drivers and performance levers across multiple facets of the multiplex assay market. When viewed through the lens of product type, consumables command foundational importance due to their essential role in assay execution, with beads and probes, microplates, and reagents and kits serving as critical building blocks. Instruments, ranging from flow cytometers and fluorescence detection systems to luminescence readers and mass spectrometers, represent the technological backbone that enables multiplex detection. Concurrently, service offerings such as assay development, data analysis, and sample testing provide the expertise necessary to translate raw data into actionable insights, while software and analysis tools streamline workflow integration and enhance interpretive accuracy.
Examining assay type segmentation highlights clear differentiation between cell-based, nucleic acid–based, and protein-based approaches, each designed to address specific analytical objectives and sensitivity requirements. Within the application arena, clinical diagnostics leverages multiplex assays for autoimmune disease diagnosis, cardiovascular and infectious disease testing, and oncology screening, whereas environmental testing and food safety assessments rely on these assays to detect contaminants and pathogens with robust specificity. Research and development endeavors benefit from multiplex platforms in biomarker validation, drug discovery and development, genomics, and proteomics research, underpinning early-stage innovation.
Finally, end-user segmentation illustrates how academic and research institutes, contract research organizations, diagnostic laboratories, hospitals, and pharmaceutical and biotechnology companies adopt tailored multiplex solutions. This granular perspective underscores the necessity for flexible assay formats, scalable instrument configurations, and comprehensive service portfolios designed to meet the evolving demands of each stakeholder group.
Analyzing Regional Market Variations and Growth Drivers Across Americas, Europe Middle East Africa, and Asia Pacific for Multiplex Assays
Regional dynamics in the multiplex assay market reflect diverse growth trajectories driven by distinct economic, regulatory, and infrastructure factors. In the Americas, substantial public and private investment in precision medicine initiatives has catalyzed demand for advanced multiplex platforms, particularly in clinical diagnostics and pharmaceutical R&D. North American laboratories benefit from well‐established regulatory frameworks and extensive reimbursement pathways, which accelerate adoption rates and support the localization of manufacturing capabilities.
Meanwhile, Europe, the Middle East, and Africa exhibit a mosaic of market conditions: strong academic research institutions in Western Europe drive procurement of cutting‐edge instruments, while emerging economies in the Middle East and Africa demonstrate growing interest in low‐cost, multiplex‐based environmental monitoring and infectious disease management solutions. Harmonized regulatory initiatives across the European Union further facilitate cross‐border collaborations and streamline product approvals.
In the Asia‐Pacific region, robust industrial ecosystems and government programs aimed at biotechnology innovation have stimulated significant growth in multiplex assay utilization. Countries such as China, Japan, and South Korea are investing heavily in next‐generation sequencing, proteomics research, and diagnostic automation, which collectively bolster demand for high‐throughput multiplex platforms and localized service centers.
Profiling Leading Industry Players and Their Strategic Initiatives That Are Shaping the Future of Multiplex Assays
Industry leaders are driving innovation in the multiplex assay space through targeted strategic initiatives and collaborative partnerships. Leading consumables suppliers are expanding their portfolios to include next‐generation beads, probes, and reagent kits optimized for enhanced specificity and multiplexing capacity. Instrument manufacturers are investing in modular architectures that integrate flow cytometry, optical detection, and mass spectrometry modules onto unified platforms, enabling seamless transition between assay formats.
Service providers are bolstering their offerings with data analytics and bioinformatics capabilities, leveraging artificial intelligence to accelerate result interpretation and facilitate real‐time decision support. At the same time, software developers are introducing cloud‐based analytics suites with intuitive interfaces, robust data security measures, and interoperability with laboratory information management systems. Meanwhile, established life science companies and emerging startups are forging co‐development agreements to accelerate the validation and commercialization of novel multiplex assays in diagnostic and research applications, thereby expanding the market’s innovation pipeline and competitive landscape.
Strategic Guidance for Industry Leaders on Maximizing Opportunities and Mitigating Risks in the Multiplex Assay Market
To capitalize on the evolving multiplex assay landscape, industry leaders should adopt a multi‐pronged strategy that aligns innovation with market demands. First, investing in flexible modular instrument platforms will enable rapid adaptation to emerging assay types and customization for specific applications. By prioritizing interoperable consumable formats and open‐architecture software solutions, organizations can foster ecosystem partnerships and mitigate risks associated with proprietary lock‐in.
Second, forging strategic alliances with contract research organizations and academic centers can accelerate assay validation and broaden access to niche expertise. Third, embedding advanced analytics and machine learning into multiplex workflows will enhance assay sensitivity and specificity, facilitating predictive insights and streamlined regulatory submissions. Additionally, engaging proactively with policymakers and standards organizations will ensure alignment with evolving validation requirements and reimbursement pathways, thereby reducing time‐to‐market.
Finally, cultivating a customer‐centric service model that offers end‐to‐end support-from assay development through data interpretation-will differentiate organizations in an increasingly competitive marketplace and drive sustained revenue growth.
Methodical Framework and Analytical Processes Employed to Ensure Comprehensive and Unbiased Multiplex Assay Market Research
This research employed a rigorous, multi‐layered methodology designed to deliver comprehensive, unbiased insights into the multiplex assay market. Primary research activities included in‐depth interviews with key opinion leaders, senior R&D executives, and regulatory experts across diagnostic, environmental, and food testing laboratories. These qualitative engagements were complemented by a structured survey administered to a global panel of end users, instrument manufacturers, and service providers to capture quantitative perspectives on technology adoption, workflow challenges, and growth priorities.
Secondary research involved an exhaustive review of scientific literature, patent filings, regulatory guidance documents, and industry white papers to map the evolution of multiplex assay technologies and identify emerging usage scenarios. Data triangulation techniques were applied to reconcile primary and secondary findings, ensuring validation and consistency of insights. Finally, proprietary analytical frameworks were leveraged to assess market dynamics, competitive positioning, and technological roadmaps, delivering a robust foundation for strategic decision‐making and actionable recommendations.
Synthesizing Key Findings and Strategic Imperatives to Drive Informed Decision Making in the Multiplex Assay Domain
Over the course of this analysis, key trends have converged to illuminate the multiplex assay market’s trajectory: technological convergence is driving enhanced assay performance and data richness; regulatory momentum is reducing barriers to clinical adoption; and supply chain adaptation is fostering greater resilience. By integrating segmentation insights with regional and competitive dynamics, stakeholders can identify high‐value opportunities and tailor their strategies to the nuanced needs of diverse end users.
As the market continues to evolve, the interplay between consumables innovation, instrument modularity, and advanced data analytics will determine the leaders of tomorrow. Organizations that embrace interoperable platforms, collaborative partnerships, and customer‐centric service models will be best positioned to navigate emerging challenges and unlock new avenues for growth. Ultimately, this synthesis underscores the critical importance of a proactive, integrated approach to multiplex assay development, commercialization, and deployment.
Note: PDF & Excel + Online Access - 1 Year
Unlocking the Transformative Power and Strategic Significance of Multiplex Assays in Advancing Analytical Capabilities Across Diverse Industries
Multiplex assays have emerged as a pivotal analytical approach that empowers scientists and decision-makers with simultaneous detection and quantification of multiple analytes in a single assay. By integrating advanced detection technologies with robust data analysis platforms, these assays streamline workflows, enhance data richness, and significantly reduce sample volume requirements. In recent years, academic and industrial laboratories alike have recognized the strategic value of multiplex assays in accelerating research and development timelines, facilitating diagnostic innovation, and optimizing quality control processes across a diverse range of applications.
Furthermore, rapid technological advancements have enabled a shift from traditional single-analyte assays to multiplex formats that accommodate complex biological matrices with higher throughput and greater sensitivity. Consequently, researchers can now address multifactorial questions in areas such as biomarker validation, genomics, and proteomics with unprecedented efficiency. Ultimately, the adoption of multiplex assays represents a transformative milestone in analytical science, setting the stage for more precise, cost-effective, and scalable solutions that will shape the future of diagnostics, environmental monitoring, food safety testing, and beyond.
How Convergence of Technological Innovations and Interdisciplinary Approaches Is Redefining Multiplex Assay Capabilities
Recent years have witnessed an accelerating convergence of technological innovation and cross-disciplinary collaboration that is redefining the multiplex assay landscape. As microfluidic platforms, advanced optical detection systems, and mass spectrometry techniques mature, they are increasingly integrated into hybrid workflows that deliver richer datasets and enhanced dynamic range. Moreover, the proliferation of machine learning algorithms and cloud-based analytics has facilitated real-time interpretation of complex multiplex results, driving a paradigm shift from reactive to predictive decision-making.
In parallel, regulatory bodies have begun to issue updated guidance that acknowledges the unique advantages and validation requirements of multiplex formats, thereby reducing barriers to clinical adoption and commercial distribution. Additionally, academic consortia and industry partnerships are fostering standardized protocols and reagent libraries, enhancing reproducibility and interoperability across laboratories. This collective momentum is transforming multiplex assays from niche research tools into mainstream platforms that underpin next-generation diagnostics, personalized medicine initiatives, and advanced environmental and food safety monitoring.
Examining the Far-Reaching Consequences of New Tariff Measures on Multiplex Assay Supply Chains and Cost Structures
The implementation of revised United States tariff measures in 2025 has introduced notable complexities to the global multiplex assay supply chain. As import duties on key assay components-including beads, probes, specialty reagents, and detection instruments-have increased, manufacturers and end users are compelled to reassess sourcing strategies and cost structures. Consequently, many stakeholders are exploring nearshoring options to mitigate exposure to tariff volatility, while others are negotiating long-term supplier agreements to lock in more favorable terms.
However, the impact extends beyond procurement expenses. Tariff-induced lead time extensions and logistical challenges have prompted laboratories to adopt lean inventory management practices and diversify vendor portfolios. Furthermore, heightened cost pressures have accelerated interest in digital assay formats and modular instrument platforms that minimize dependency on proprietary consumables. Despite these headwinds, the industry has responded with adaptive strategies that preserve both operational continuity and innovation momentum, ensuring that multiplex assay development remains resilient and future-ready.
Uncovering Critical Market Dynamics Through Detailed Segmentation Across Product, Assay, Application, and End User Domains
A comprehensive segmentation analysis reveals distinct growth drivers and performance levers across multiple facets of the multiplex assay market. When viewed through the lens of product type, consumables command foundational importance due to their essential role in assay execution, with beads and probes, microplates, and reagents and kits serving as critical building blocks. Instruments, ranging from flow cytometers and fluorescence detection systems to luminescence readers and mass spectrometers, represent the technological backbone that enables multiplex detection. Concurrently, service offerings such as assay development, data analysis, and sample testing provide the expertise necessary to translate raw data into actionable insights, while software and analysis tools streamline workflow integration and enhance interpretive accuracy.
Examining assay type segmentation highlights clear differentiation between cell-based, nucleic acid–based, and protein-based approaches, each designed to address specific analytical objectives and sensitivity requirements. Within the application arena, clinical diagnostics leverages multiplex assays for autoimmune disease diagnosis, cardiovascular and infectious disease testing, and oncology screening, whereas environmental testing and food safety assessments rely on these assays to detect contaminants and pathogens with robust specificity. Research and development endeavors benefit from multiplex platforms in biomarker validation, drug discovery and development, genomics, and proteomics research, underpinning early-stage innovation.
Finally, end-user segmentation illustrates how academic and research institutes, contract research organizations, diagnostic laboratories, hospitals, and pharmaceutical and biotechnology companies adopt tailored multiplex solutions. This granular perspective underscores the necessity for flexible assay formats, scalable instrument configurations, and comprehensive service portfolios designed to meet the evolving demands of each stakeholder group.
Analyzing Regional Market Variations and Growth Drivers Across Americas, Europe Middle East Africa, and Asia Pacific for Multiplex Assays
Regional dynamics in the multiplex assay market reflect diverse growth trajectories driven by distinct economic, regulatory, and infrastructure factors. In the Americas, substantial public and private investment in precision medicine initiatives has catalyzed demand for advanced multiplex platforms, particularly in clinical diagnostics and pharmaceutical R&D. North American laboratories benefit from well‐established regulatory frameworks and extensive reimbursement pathways, which accelerate adoption rates and support the localization of manufacturing capabilities.
Meanwhile, Europe, the Middle East, and Africa exhibit a mosaic of market conditions: strong academic research institutions in Western Europe drive procurement of cutting‐edge instruments, while emerging economies in the Middle East and Africa demonstrate growing interest in low‐cost, multiplex‐based environmental monitoring and infectious disease management solutions. Harmonized regulatory initiatives across the European Union further facilitate cross‐border collaborations and streamline product approvals.
In the Asia‐Pacific region, robust industrial ecosystems and government programs aimed at biotechnology innovation have stimulated significant growth in multiplex assay utilization. Countries such as China, Japan, and South Korea are investing heavily in next‐generation sequencing, proteomics research, and diagnostic automation, which collectively bolster demand for high‐throughput multiplex platforms and localized service centers.
Profiling Leading Industry Players and Their Strategic Initiatives That Are Shaping the Future of Multiplex Assays
Industry leaders are driving innovation in the multiplex assay space through targeted strategic initiatives and collaborative partnerships. Leading consumables suppliers are expanding their portfolios to include next‐generation beads, probes, and reagent kits optimized for enhanced specificity and multiplexing capacity. Instrument manufacturers are investing in modular architectures that integrate flow cytometry, optical detection, and mass spectrometry modules onto unified platforms, enabling seamless transition between assay formats.
Service providers are bolstering their offerings with data analytics and bioinformatics capabilities, leveraging artificial intelligence to accelerate result interpretation and facilitate real‐time decision support. At the same time, software developers are introducing cloud‐based analytics suites with intuitive interfaces, robust data security measures, and interoperability with laboratory information management systems. Meanwhile, established life science companies and emerging startups are forging co‐development agreements to accelerate the validation and commercialization of novel multiplex assays in diagnostic and research applications, thereby expanding the market’s innovation pipeline and competitive landscape.
Strategic Guidance for Industry Leaders on Maximizing Opportunities and Mitigating Risks in the Multiplex Assay Market
To capitalize on the evolving multiplex assay landscape, industry leaders should adopt a multi‐pronged strategy that aligns innovation with market demands. First, investing in flexible modular instrument platforms will enable rapid adaptation to emerging assay types and customization for specific applications. By prioritizing interoperable consumable formats and open‐architecture software solutions, organizations can foster ecosystem partnerships and mitigate risks associated with proprietary lock‐in.
Second, forging strategic alliances with contract research organizations and academic centers can accelerate assay validation and broaden access to niche expertise. Third, embedding advanced analytics and machine learning into multiplex workflows will enhance assay sensitivity and specificity, facilitating predictive insights and streamlined regulatory submissions. Additionally, engaging proactively with policymakers and standards organizations will ensure alignment with evolving validation requirements and reimbursement pathways, thereby reducing time‐to‐market.
Finally, cultivating a customer‐centric service model that offers end‐to‐end support-from assay development through data interpretation-will differentiate organizations in an increasingly competitive marketplace and drive sustained revenue growth.
Methodical Framework and Analytical Processes Employed to Ensure Comprehensive and Unbiased Multiplex Assay Market Research
This research employed a rigorous, multi‐layered methodology designed to deliver comprehensive, unbiased insights into the multiplex assay market. Primary research activities included in‐depth interviews with key opinion leaders, senior R&D executives, and regulatory experts across diagnostic, environmental, and food testing laboratories. These qualitative engagements were complemented by a structured survey administered to a global panel of end users, instrument manufacturers, and service providers to capture quantitative perspectives on technology adoption, workflow challenges, and growth priorities.
Secondary research involved an exhaustive review of scientific literature, patent filings, regulatory guidance documents, and industry white papers to map the evolution of multiplex assay technologies and identify emerging usage scenarios. Data triangulation techniques were applied to reconcile primary and secondary findings, ensuring validation and consistency of insights. Finally, proprietary analytical frameworks were leveraged to assess market dynamics, competitive positioning, and technological roadmaps, delivering a robust foundation for strategic decision‐making and actionable recommendations.
Synthesizing Key Findings and Strategic Imperatives to Drive Informed Decision Making in the Multiplex Assay Domain
Over the course of this analysis, key trends have converged to illuminate the multiplex assay market’s trajectory: technological convergence is driving enhanced assay performance and data richness; regulatory momentum is reducing barriers to clinical adoption; and supply chain adaptation is fostering greater resilience. By integrating segmentation insights with regional and competitive dynamics, stakeholders can identify high‐value opportunities and tailor their strategies to the nuanced needs of diverse end users.
As the market continues to evolve, the interplay between consumables innovation, instrument modularity, and advanced data analytics will determine the leaders of tomorrow. Organizations that embrace interoperable platforms, collaborative partnerships, and customer‐centric service models will be best positioned to navigate emerging challenges and unlock new avenues for growth. Ultimately, this synthesis underscores the critical importance of a proactive, integrated approach to multiplex assay development, commercialization, and deployment.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of AI and machine learning for high-dimensional multiplex assay data analytics and interpretation
- 5.2. Development of portable point-of-care multiplex diagnostics for rapid detection of emerging infectious disease variants
- 5.3. Expansion of high-plex spatial proteomics multiplex assays for tumor microenvironment characterization in oncology
- 5.4. Adoption of microfluidic lab-on-a-chip multiplex platforms enabling ultra-sensitive assays with minimal sample volumes
- 5.5. Growth of multiplex PCR panels for simultaneous detection of antimicrobial resistance genes in clinical microbiology
- 5.6. Emergence of bead-based multiplex flow cytometry assays for comprehensive immune profiling in CAR-T cell therapy research
- 5.7. Increasing collaboration between assay developers and biopharma for multiplex companion diagnostics in precision medicine trials
- 5.8. Implementation of digital droplet multiplex PCR systems for absolute quantification of sparse mutation panels in liquid biopsy analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Multiplex Assays Market, by Product Type
- 8.1. Consumables
- 8.1.1. Beads & Probes
- 8.1.2. Microplates
- 8.1.3. Reagents & Kits
- 8.2. Instruments
- 8.2.1. Flow Cytometers
- 8.2.2. Fluorescence Detection Systems
- 8.2.3. Luminescence Readers
- 8.2.4. Mass Spectrometers
- 8.3. Services
- 8.3.1. Assay Development Services
- 8.3.2. Data Analysis Services
- 8.3.3. Sample Testing Services
- 8.4. Software & Analysis Tools
- 9. Multiplex Assays Market, by Assay Type
- 9.1. Cell-Based Multiplex Assays
- 9.2. Nucleic Acid-Based Multiplex Assays
- 9.3. Protein-Based Multiplex Assays
- 10. Multiplex Assays Market, by Application
- 10.1. Clinical Diagnostics
- 10.1.1. Autoimmune Disease Diagnosis
- 10.1.2. Cardiovascular Disease Testing
- 10.1.3. Infectious Disease Testing
- 10.1.4. Oncology
- 10.2. Environmental Testing
- 10.3. Food Safety Testing
- 10.4. Research & Development
- 10.4.1. Biomarker Validation
- 10.4.2. Drug Discovery & Development
- 10.4.3. Genomics Research
- 10.4.4. Proteomics Research
- 11. Multiplex Assays Market, by End User
- 11.1. Academic & Research Institutes
- 11.2. Contract Research Organizations (CROs)
- 11.3. Diagnostic Laboratories
- 11.4. Hospitals
- 11.5. Pharmaceutical & Biotechnology Companies
- 12. Multiplex Assays Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Multiplex Assays Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Multiplex Assays Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott Laboratories
- 15.3.2. Abcam Limited by Danaher Corporation
- 15.3.3. Agilent Technologies, Inc.
- 15.3.4. Antigenix America, Inc.
- 15.3.5. Becton, Dickinson and Company
- 15.3.6. Bio-Rad Laboratories, Inc.
- 15.3.7. Bio-Techne Corporation
- 15.3.8. Cayman Chemical Company
- 15.3.9. Charles River Laboratories International, Inc.
- 15.3.10. Enfer Group
- 15.3.11. Enzo Life Sciences, Inc.
- 15.3.12. Flagship Biosciences Inc.
- 15.3.13. Future Diagnostics Solutions B.V.
- 15.3.14. Gnome Diagnostics & Gnome Sciences
- 15.3.15. Illumina, Inc.
- 15.3.16. Merck KGaA
- 15.3.17. MESO SCALE DIAGNOSTICS, LLC
- 15.3.18. Novatein Biosciences Inc.
- 15.3.19. Protavio Ltd.
- 15.3.20. Siemens Healthineers AG
- 15.3.21. Solis BioDyne OÜ
- 15.3.22. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
